Lunai Bioworks Inc. has made significant changes to the employment agreement of its CEO, David Weinstein, as part of a broader strategy to navigate challenges in the pharmaceutical industry. The company has also initiated the process to withdraw its common stock from the Nasdaq stock exchange.

On November 6, 2026, Lunai Bioworks entered into an Amended and Restated Employment Agreement with Weinstein, effective from October 14, 2026. This amendment reflects a reduction in his annual base salary from $400,000 to $275,000. Additionally, Weinstein will not receive any bonuses or equity awards unless specifically approved by the Board of Directors.

The decision to amend the CEO's contract comes amid a broader restructuring within the company. Weinstein's October salary of $28,150.68 will be deferred and paid in a lump sum by March 15, 2027, or upon termination of his employment.

Weinstein has waived several rights under his previous agreement, including a severance package estimated at $200,000, which would have provided six months of base salary, continued benefits, and accelerated vesting of equity awards in the event of termination without cause. Under the new terms, he will only be entitled to earned but unpaid salary and unreimbursed business expenses upon termination.

These changes are part of Lunai's efforts to adapt to the evolving landscape of the pharmaceutical preparations industry, where companies are increasingly focusing on cost management and operational efficiency. The company’s decision to withdraw its stock from Nasdaq, as indicated in its recent filings, further emphasizes its shift in strategy.

Lunai Bioworks has a history of restructuring, having previously changed its name from Renovaro Inc. and Renovaro Biosciences Inc. in recent years. This latest move to amend the CEO's agreement and withdraw from Nasdaq could signal a significant pivot in its operational focus.

As Lunai Bioworks navigates these changes, competitors in the pharmaceutical preparations sector may closely observe its strategic decisions. The company's ability to adapt could influence its standing in a highly competitive market.

Looking ahead, Lunai Bioworks has not specified any immediate next steps following the filing. The company continues to operate under its amended agreement with Weinstein, which is set to expire on December 28, 2026, unless extended.

The filing, with accession number 0001731122-26-001434, provides a detailed overview of the recent changes within Lunai Bioworks and highlights the ongoing adjustments in the pharmaceutical industry.